![Colin Macaulay](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Colin Macaulay
Oprichter bij Viron Therapeutics, Inc.
Profiel
Colin Macaulay is the founder.
He founded Viron Therapeutics, Inc. in 1997 and currently holds the title of Senior Director-Research & Development.
Dr. Macaulay obtained a doctorate degree from the University of Alberta in 1989.
Actieve functies van Colin Macaulay
Bedrijven | Functie | Begin |
---|---|---|
Viron Therapeutics, Inc.
![]() Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Oprichter | 13-10-2009 |
Opleiding van Colin Macaulay
University of Alberta | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Viron Therapeutics, Inc.
![]() Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |